Skip to content

The Plasmodium vivax malaria project of ITSL elected as part the fund’s portfolio of the EU Malaria Fund

The EU Malaria Fund is a public-private partnership between the European Union, International Organizations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. It has been initiated by kENUP Foundation.

The EU Malaria fund works with a portfolio of promising projects. Compared to Oncology, TB or HIV, there are only very few companies active in the Malaria domain. Those originate from technology transfer out of many of Europe‚Äôs leading research organizations, and are not yet invested in by a large pharmaceutical company.  Here, we prefer to fund platform projects, allowing for secondary exploitations of their anti-malaria assets, for example into COVID-19 and other important under-served infectious diseases.